التفاصيل البيبلوغرافية
| العنوان: |
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. |
| المؤلفون: |
Sandner, Sigrid E1 (AUTHOR) sigrid.sandner@meduniwien.ac.at, Schunkert, Heribert1,2 (AUTHOR), Kastrati, Adnan2,3 (AUTHOR), Wiedemann, Dominik1 (AUTHOR), Misfeld, Martin4 (AUTHOR), Böning, Andreas5 (AUTHOR), Tebbe, Ulrich6 (AUTHOR), Nowak, Bernd7 (AUTHOR), Stritzke, Jan8 (AUTHOR), Laufer, Günther1 (AUTHOR), Scheidt, Moritz von2,3 (AUTHOR), Investigators, for the TiCAB (AUTHOR) |
| المصدر: |
European Journal of Cardio-Thoracic Surgery. Apr2020, Vol. 57 Issue 4, p732-739. 8p. |
| مصطلحات موضوعية: |
*CORONARY artery bypass, *ASPIRIN, *ARTERIAL grafts, *MYOCARDIAL infarction, *CEREBRAL revascularization, *TICAGRELOR |
| مستخلص: |
Open in new tab Download slide Open in new tab Download slide OBJECTIVES We evaluated the effect of ticagrelor monotherapy on outcomes after multiple arterial grafting (MAG) or single arterial grafting (SAG) in coronary artery bypass grafting (CABG). METHODS In a post hoc , non-randomized analysis of the TiCAB (Ticagrelor in CABG; ClinicalTrials.gov NCT01755520) trial, we compared event rates for ticagrelor versus aspirin in patients undergoing MAG and SAG. Primary outcome was the composite of cardiovascular death, non-fatal myocardial infarction (MI), stroke or repeat revascularization 1 year after CABG. Secondary outcomes included individual components of the primary end point, all-cause death and bleeding. RESULTS Among 1753 patients, 998 patients underwent MAG and 755 patients underwent SAG. There was no significant difference in the 1-year primary composite outcome for ticagrelor versus aspirin with MAG [7.2% vs 7.9%; hazard ratio (HR) 0.90, 95% confidence interval (CI) 0.57–1.43; P = 0.66] or SAG (12.3% vs 8.6%; HR 1.47, 95% CI 0.93–2.31; P = 0.10). Event rates for cardiovascular death, MI, stroke, repeat revascularization and all-cause death were similar for both treatment groups with MAG and SAG. No significant difference in major bleeding was observed for ticagrelor versus aspirin with MAG (2.6% vs 2.7%; HR 0.95, 95% CI 0.44–2.05; P = 0.90) or SAG (5.8% vs 4.0%; HR 1.49, 95% CI 0.77–2.89; P = 0.24). CONCLUSIONS In patients undergoing either MAG or SAG in the TiCAB trial, ticagrelor monotherapy compared with aspirin did not affect the rate of cardiovascular death, non-fatal MI, stroke or repeat revascularization, or the rate of bleeding, at 1 year after CABG. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder